Schedule 13G ownership disclosure

Oramed Pharmaceuticals, Inc.

Common Stock par value $0.012 per share · CUSIP: 68403P203

Event date: 2025-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • BML Investment Partners, L.P.

    Shares: 3,167,231 · Class: 7.9%

  • Leonard Braden Michael

    Shares: 3,287,531 · Class: 8.3%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001373604-26-000012
Form type
SCHEDULE 13G/A
Filer
BML Investment Partners, L.P.
CIK
CIK 1373604
Filed
Feb 09, 2026
Reporting period
Dec 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub